POLB 001 poster to be presented at EHA 2026 Congress
Poolbeg Pharma, a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it will present data on POLB 001 at the European Hematology Association Congress ("EHA"), taking place 11-14 June 2026 in Stockholm, Sweden.
The abstract, which is available online, outlines further evidence of POLB 001's potential to prevent cancer immunotherapy-induced Cytokine Release Syndrome (CRS). The data presented at EHA will include in vivo models showing the capacity of POLB 001 to reduce multiple key CRS-related cytokines (including TNF, IFNγ, and IL-6) and in vitro data showing that POLB 001 can inhibit cytokine production without impairing bispecific antibody-induced tumour cell killing.
EHA is one of the world's leading scientific meetings focused on haematology, bringing together clinicians, researchers, pharmaceutical companies and healthcare professionals to present and discuss the latest advances in blood disorders and related treatments. The congress serves as a major international platform for the presentation of important data, translational research and emerging therapeutic developments across areas including myeloma, leukemia, lymphoma, and other hematological diseases.
Title: POLB 001, an oral P38 MAPK Inhibitor for the Prevention of Cytokine Release Syndrome
Poster Session: Poster Session 2
Session Date and Time: Saturday, 13 June 2026, 18:45 - 19:45 CEST
Location: Stockholmsmässan exhibition centre, Stockholm, Sweden
Authors: Liam Tremble, Paula Maguire, Meena Arora, Joe Froggatt, Jeremy Skillington, Brendan Buckley, Rakesh Popat, Emma Searle.
Abstract Code: PS1845
To schedule a meeting with the Company, please contact [email protected].
Liam Tremble, Principal Scientist of Poolbeg Pharma, said:
We look forward to sharing this important data at the European Hematology Association Congress, one of the world's leading forums for advancing haematology research. The findings highlight the potential of POLB 001 to reduce key drivers of CRS while preserving anti-tumour activity. We believe POLB 001 could transform the cancer immunotherapy field through the prevention of CRS, improving patient quality of life and expanding the number of patients that can receive these life-saving cancer immunotherapies.
